drugset / Trial / NCT03113240

Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients

NCT03113240

Phase 3 Completed 60 enrolled Shahid Beheshti University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Glutamine-induced recovery in intestinal barrier function by reducing bacterial translocation was demonstrated in previous studies. In this trial, intensive care unit patients with enteral feeding will receive either enteral glutamine or maltodextrin as placebo for 10 days and the effects of the intervention on intestinal permeability will be assessed.

Timeline

Start
2017-04-01
Primary completion
2017-10-01
Completion
2017-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glutamine Other / unclassified 0.3 g/kg Other

Indications

No indication recorded.